Article
Targeting KRAS mutant cancers: from druggable therapy to drug resistance.
Molecular cancer - 4 Aug 2022
Zhu Chunxiao, Guan Xiaoqing, Zhang Xinuo, Luan Xin, Song Zhengbo, Cheng Xiangdong, Zhang Weidong, Qin Jiang-Jiang
Abstract excerpt
Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) is the most frequently mutated oncogene, occurring in a variety of tumor types. Targeting KRAS mutations with drugs is challenging because KRAS is considered undruggable due to the lack of classic drug binding sites. Over the past 40 years, great efforts have been made to explore routes for indirect targeting of KRAS mutant cancers, including KRAS expression,...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.